Loebbert
Andreas Loebbert, Chur CH
Patent application number | Description | Published |
---|---|---|
20110236962 | Calibratable sensor unit for reaction vessels - The present invention relates to a calibratable sensor unit for a reaction vessel, such as for example a fermenter ( | 09-29-2011 |
20130288359 | CALIBRATABLE SENSOR UNIT FOR REACTION VESSELS - The invention relates to a reaction vessel with a sensor unit. The reaction vessel comprising a reaction space configured to be connected with the sensor unit that comprises at least one sensor device configured to be calibrated, at least one compartment containing a calibrating agent, and a housing. The sensor unit is arranged to calibrate the at least one sensor device by contact with the calibrating agent before chemical or physical parameters of a measurement substance are measured, wherein the at least one sensor device is further configured such that the relative movement between the at least one sensor device and the at least one compartment is irreversible. The at least one sensor device is movable relative to the at least one compartment from an initial position into a measurement readiness position. The reaction vessel and the sensor unit can be sterilised or are sterilised jointly. | 10-31-2013 |
20130291618 | CALIBRATABLE SENSOR UNIT FOR REACTION VESSELS - The present invention relates to a calibration method of a sensor unit connected to a reaction vessel, wherein the sensor unit comprises at least one sensor device configured to be calibrated, at least one compartment containing a calibrating agent, and a housing. The method comprising inserting a sensitive element of the at least one sensor device into a compartment of the sensor unit containing a calibrating agent, withdrawing the sensitive element from the compartment; inserting the sensitive element into the reaction vessel and locking the sensor device in position, wherein the steps of the method are irreversible. | 11-07-2013 |
Ralf Loebbert, Speyer DE
Patent application number | Description | Published |
---|---|---|
20100028359 | ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF - The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid B and advanced glycation-end-products. | 02-04-2010 |
20130149313 | ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF - The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products. | 06-13-2013 |
Ralph Loebbert, Heidelberg DE
Patent application number | Description | Published |
---|---|---|
20100226915 | AGER-Peptides and Use Thereof - The present invention relates to the identification, functionality and use of domains from the N terminus of the receptor for Advanced Glycation End Products (AGER). These domains, called receptor mulitimerization epitope (RME), are highly conserved in all AGER protein sequences. They represent the mediators for AGER self-association and heteromerization with other proteins. The invention likewise relates to the identification, functionality and use of peptides derived from the C domain of AGER (AGER-CDP). The AGER RMEs and AGER-CDPs of the invention are suitable as target for identifying AGER ligands which modulate the natural ligand interaction; as immunogen for active or passive immunization of individuals, as diagnostic means for identifying immunogenic reactions, and as peptide ligands for modulating protein-protein interactions involving AGER. | 09-09-2010 |